Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates.
Androgen-deprivation therapy, a mainstay in the treatment of locally advanced and metastatic prostate cancer, is associated with significant bone loss and related complications, such as fracture. Bisphosphonates, osteoclast inhibitors, are effective in preventing skeletal-related events in patients with metastatic prostate cancer and also in preventing bone loss in patients with locally advanced disease. Understanding the management of bone health, including identifying patients at risk, the most appropriate therapy, and monitoring and managing side effects, is critical. This review provides the most recent bone health risk factor and bisphosphonate data available for prostate cancer patients.
Polascik
T J
TJ
Duke Prostate Center and Division of Urologic Surgery, Duke University, Durham, NC 27710, USA. polas001@mc.duke.edu
D000726:Androgen Antagonists / Q000009:adverse effects*; D001847:Bone Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000628:therapy*
D000726:Androgen Antagonists; D004164:Diphosphonates